Survey: Providers, Admins Struggle to Appreciate Biosimilar Suffixes
The FDA naming convention and its utility are not well understood, and “poor” biosimilar knowledge may be partly to blame, investigators report.
High Patient Retention Observed for Multiple Etanercept Switches
Investigators said their study is valuable because biosimilar switching is likely to increase for economic reasons.
High Adherence Noted Among Infliximab Biosimilar Users
Investigators looked at adherence in patients who switched from reference infliximab during treatment for rheumatologic and gastrointestinal treatment.
Multibiomarker Test Reads Out Positive in 2 Pfizer-Sponsored Studies
A multibiomarker disease activity score looks at serum protein activity for a more sensitive evaluation of biosimilarity, investigators said at the American College of Rheumatology Convergence 2020 meeting.
ACR Abstract Roundup: Pfizer and Celltrion Agents Demonstrate Safety, Efficacy
Poster presentations at the American College of Rheumatology (ACR) Convergence 2020 meeting shed light on performance of adalimumab versions.
Celltrion's CT-P17 Adalimumab Biosimilar Candidate Demonstrates Equivalence
Separate studies including one on application methods for CT-P17 were reported at the American College of Rheumatology Convergence 2020 meeting.
